Приклади вживання Non-alcoholic fatty Англійська мовою та їх переклад на Українською
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
Is the incidence of non-alcoholic fatty hepatosis.
Non-alcoholic fatty liver disease and metabolic disorders: what is primary?
Silymarin: An option to treat non-alcoholic fatty liver disease.”.
Non-alcoholic fatty liver disease obesity quality of life depressive disorders.
The multifactorial pathogenesis of non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease has been on the rise over the past two decades.
The rifaximine efficacy in the treatment of non-alcoholic fatty liver disease.
Influence of non-alcoholic fatty liver disease on course of ischemic heart disease during two-years observation.
Another study that supports this looked at the effects of curcumin on non-alcoholic fatty liver disease.
The pathogenic mechanisms of development of non-alcoholic fatty liver disease(NAFLD) have been elucidatedin the paper.
Keywords: non-alcoholic fatty liver disease, intestinal bacterial overgrowth syndrome, prophylaxis, treatment, rifaximine.
In recent years the mostcommon liver disease in the world is a non-alcoholic fatty liver disease(NAFLD).
Keywords: non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome, free fat acids, micro-RNA, endothelial dysfunction.
This shows that curcumin could have a positive effect on non-alcoholic fatty liver disease in these higher dosages.
Keywords: non-alcoholic fatty liver disease,non-alcoholic steatohepatitis, metabolic syndrome, obesity, diabetes, tumor necrosis factor, interleukin.
Assessment of fetuin-A in patients with comorbidity of non-alcoholic fatty liver disease and arterial hypertension.
Non-alcoholic fatty liver disease comorbidity concomitant pathology subclinical thyroidism lipid peroxidation antioxidant defense system antioxidant medicines differentiated approach to the treatment.
Assessment of quality of life and psychological state in patients with non-alcoholic fatty liver disease and overweight.
Keywords: coronary heart disease, non-alcoholic fatty liver disease, subclinical atherosclerosis, leptin levels, postprandial hypertriglyceridemia.
Endothelial dysfunction in patients with postinfarction ischemic cardiomyopathy combined with non-alcoholic fatty liver disease.
The role of exercise in the prevention and treatment of non-alcoholic fatty liver disease(NAFLD), a consequence of obesity, is well established.
The potential role of kallistatin as a new biomarker in non-invasivediagnostics of non-alcoholic fatty liver disease with hypertension.
The relevance of work is determined by wide occurrence of non-alcoholic fatty liver disease(NAFLD) often combined with other comorbidities and ambiguity of recommendations about treatment of such patients.
BazylevychEndothelial dysfunction in patients with postinfarction ischemic cardiomyopathy combined with non-alcoholic fatty liver disease O.S. Sychov, A. O.
Global medical community adopted proven protocols for treatment of non-alcoholic fatty liver disease, viral hepatitis and other dangerous diseases.
Atherosclerosis of cerebral arteries, leptin levels andpostprandial hypertriglyceridemia in patients with coronary heart disease combined with non-alcoholic fatty liver disease, depending on the body mass index.
Assessment of quality of life and psychological state in patients with non-alcoholic fatty liver disease and overweight Psychosomatic Medicine and General Practice.
Development of highly informative methods of early diagnostics and prediction of non-alcoholic fatty liver disease in patients with metabolic syndrome;
In-depth study of pathogenetic mechanisms of the most important diseases of the liver andthe gastrointestinal tract: non-alcoholic fatty and alcoholic liver diseases, gastroesophageal reflux disease;